Parliamentary Search

Written question asked by Apsana Begum (Labour) on Thursday, 16 July 2026, in the House of Commons. It was due for an answer on Wednesday, 2 September 2026. It was answered by James Frith (Labour) on Monday, 7 September 2026 on behalf of the Department of Health and Social Care.

Drugs: USA

Question

To ask the Secretary of State for Health and Social Care, whether his Department has considered the potential merits of publishing an impact assessment for the US-UK Arrangement on Pharmaceuticals Pricing and Tariffs in which commercially sensitive material is redacted.

Answer

The UK-US Arrangement on Pharmaceutical Pricing and Tariffs is intended to support National Health Service patients’ access to innovative medicines, while strengthening the United Kingdom’s life sciences sector. The terms of the arrangement have been published in full, and we have answered numerous questions about its operation in parliamentary questions and debate.

Publishing a redacted impact assessment would not aid understanding around the deal. The analysis depends on assumptions about future medicines approvals, NHS uptake, global pricing policies, and wider commercial discussions. Removing commercially sensitive material would remove much of the context needed to understand that analysis properly.

Secondary information

Type
Written question
Reference
19476
Session
2026-27
Subjects
Disclosure of information Drugs Import duties Prices USA Impact assessments
Link
View this Written question on www.parliament.uk